

### The 12th Biennial Congress of the Anaerobe Society of the Americas

The 37th Congress of the Society for Microbial Ecology and Disease

Westin River North Hotel, Chicago, IL USA — June 28-July 1, 2014

## Preliminary Program

15:4

15:4

17:1

17:4

### SATURDAY, JUNE 28, 2014


8:00 Registration (thru 17:00)
9:00 Anaerobic Identification & Susceptibility Workshop

### SUNDAY, JUNE 29, 2014

7:00 Registration / Breakfast / Exhibits 8:00 Welcome Dale Gerding, M.D. & Andrew Onderdonk, Ph.D. Session I: Ecology of the Microbiota 8:10 Chair: Wendy Garrett, M.D., Ph.D. GI Microbiome and Immune Modulation Rick S. Blumberg, M.D. Brigham and Women's Hospital Boston, MA USA Computational Approaches for the Human Microbiome in Health and Disease Curtis Huttenhower, Ph.D. Harvard University Cambridge, MA USA Functional Characterisation of a Unique Homologue of Ubiquitin Produced by the Commensal Gastro-Intestinal Bacterium Bacteroides fragilis Maria T. Kowal, Ph.D. University of Edinburgh Edinburgh, United Kingdom 9:15 Break 9:30 Session II: Keynote Chair: Dale Gerding, M.D. Long-Term Consequences of Antibiotic Use Martin J. Blaser, M.D. Human Microbiome Program New York University Langone Medical Center New York, NY USA 10:30 Break 10:40 Session III: Microbiota: Reaching Beyond the Gut Chairs: Cindy Sears, M.D. & Bennett Lorber, M.D. Microbiota and Cancer Therapy Romina S. Goldszmid. Ph.D. Center for Cancer Research, NCI, NIH Frederick, MD USA What's Buggin You?: The Role of the Gut Microbiome in Central Nervous System Disease Lloyd H. Kasper, M.D. Geisel School of Medicine, Dartmouth College Hanover, NH USA The Role of Early-Life Microbiota in Shaping Adult Body Composition Laurie M. Cox, Ph.D. NYU Langone Medical Center New York, NY USA 12:00 Lunch / Exhibits 13:00 Poster Session 1 14:00 Session VI: Beneficial Microbiome Members Chair: Eugenia Bezirtzoglou, M.D., Ph.D. Probiotics Rules and Problems Tore Midtvedt, M.D., Ph.D. Karolinska Institute

Stockholm, Sweden

	Probiotics, Immunobiotics and Diet in Predictive, Attendance Unknown Preventive and Personalised Medicine Nadiya Boyko, D.Sc. Uzhhorod National University Ukraine
	Diversity of Intestinal Lactic Acid Bacteria and Health <b>Marika Mikelsaar, Ph.D.</b> University of Tartu Estonia
	Bifidobacteria and Rheumatism <b>Marie-Bénédicte Romond, Ph.D.</b> University of Lille Nord de France Lille France
	Probiotics in Prevention of Chronic Diseases Alojz Bomba, D.Sc. Pavol Jozef Šafárik University Košice, Slovak Republic
	In vitro Investigation of Brachyspira pilosicoli-Host Metabolic Interactions <b>Caroline I. Le Roy</b> The University of Reading Reading, United Kingdom
0	Break
5	Session V: Anaerobes in the Oral Cavity Chair: Purima Kumar, D.D.S., Ph.D. Fusobacterium nucleatum: A Commensal-Turned Pathogen Yiping Han, Ph.D. Case Western Reserve University Cleveland, OH USA
	Oral Bacteria and Systemic Disease: P. gingivalis Can Cause What?! Richard Lamont, Ph.D. University of Louisville Louisville, KY USA
	Oral Anaerobes in Health and Disease: 2014 Highlights Georg Conrads, Ph.D. University Hospital Aachen-Germany
	Highly Diverse Root Canal Microbiota in Chronic Apical Periodontitis According to Illumina Sequencing <b>Reet Mändar, M.D., Ph.D.</b> University of Tartu Estonia
5	Anaerobe Society Meeting
5	Wine & Cheese Reception in Exhibit Area





# Anaerobe

### Westin River North Hotel Chicago, IL USA June 28-July 1, 2014

MONDAY, JUNE 30, 2014 14:40 Session IX: Clostridium spp: Health and Disease Chair: Carl Erik Nord, M.D. 7:00 Registration / Breakfast / Exhibits The Opportunistic Pathogen Clostridium septicum 7:30 Satellite Symposium — Sponsor: bioMerieux David M. Aronoff, M.D. A New Look at Anaerobes in the Clinical Laboratory Vanderbilt University Medical Center MALDI-ToF MS for the Identification of Anaerobes Nashville, TN USA **Dave Pincus** Life Threatening Toxin Mediated Clostridial Infections Research Fellow, Microbial Identification Dennis L. Stevens, M.D., Ph.D. R&D Microbiology, bioMérieux VA Medical Center The Importance of Susceptibility Testing of Anaerobes: Boise, ID USA When, How, Why Spores of Clostridium Engineered for Clinical Efficacy and David W. Hecht, M.D., M.B.A. Safety Cause Regression and Cure of Tumors In Vivo Senior Vice President, Clinical Affairs and Chief Medical Officer Nigel P. Minton, Ph.D. Loyola University Health System The University of Nottingham The John W. Clarke Professor and Chairman, Nottingham, United Kingdom Department of Medicine, Loyola University Medical Center Maywood, IL Clostridium sordellii Infections: Insights into the Pathogenesis of Disease 8:45 Session VI: Biofilms in Anaerobic Infections Mike J. Aldape, Ph.D. Chair: David Fredricks, M.D. VA Medical Center Biofilms vs Composition in Colon Cancer: Will There Be a Boise, ID USA Victor? Cynthia L. Sears, M.D. Identification of the Host Receptor for Clostridium perfringens Johns Hopkins University School of Medicine TpeL Toxin Indicates a Two-Receptor Model of Clostridial Baltimore, MD USA Glycosylating Toxins Panagiotis Papatheodorou, Ph.D. Gardnerella vaginalis Biofilms in Bacterial vaginosis Albert-Ludwigs-Universität Freiburg Adam J. Ratner, M.D., M.P.H. Freiburg, Germany Columbia University New York, NY USA 16.00Break Clostridium difficile Biofilms (in vitro) Session X: Whole Genome Sequencing 16:10 Adam Driks, Ph.D. Chair: Ellen Jo Baron, Ph.D. Loyola University Medical Center Whole Genome Sequencing for Crohn's Disease Bacteria in the Maywood IL USA Gut Mucosa The Microbiome in Oral Health and Disease Scot E. Dowd, Ph.D. Purnima Kumar, D.D.S, Ph.D. MR DNA The Ohio State University Shallowater, TX USA Columbus, OH USA Urine is Not Sterile: New Tools Lead to New Hypotheses 10:25 Alan J. Wolfe, Ph.D. Break Stritch School of Medicine 10:35 Session VII: Diagnostic and Laboratory Techniques Loyola University Chicago Chair: Diane Citron Maywood, IL USA Oscillibacter Who? What Shall We Do with These Session XI: Antimicrobials and Resistance 17.10New Names? Chair: Ellie J.C. Goldstein, M.D. **Diane Citron** The Drug Pipeline for Anaerobic Infections R.M. Alden Research Lab Ellie J.C.Goldstein, M.D. Culver City CA USA R.M. Alden Research Lab European Experience with Maldi-TOF MS in the Field of University of California, Los Angeles Anaerobes Santa Monica, CA USA Elisabeth Nagy, M.D., Ph.D., D.Sc. Antimicrobial Susceptibility Testing in Europe University of Szeged Carl Erik Nord, M.D. Szeged, Hungary Karolinska Institute Animal Models for Clostridium difficile Infections Stockholm, Sweden Vincent Young, M.D., Ph.D. Emergence and Evolution of an International Clone of The University of Michigan Multiresistant Bacteroides fragilis Isolates Ann Arbor, MI USA József Sóki, Ph.D. 11.50Lunch / Exhibits University of Szeged 12.50Poster Session 2 Szeged, Hungary Session VIII: The Care and Feeding of Our Intestinal Evaluation of the Antimicrobial Susceptibility Profiling of 13:50 Microbiome Tigecycline and Other Antibiotics against Clinical Isolates Chair: Andrew Onderdonk, Ph.D. Grigoria Mitropoulou, Ph.D. Functional Dairy Foods and Flora Modulation Democritus University of Thrace Eugenia Bezirtzoglou, M.D., Ph.D. Orestiada, Greece Democritus University of Thrace 18:00 Session Ends Orestiada, Greece Symposium Reception 18:15 New Antimicrobial Strategy Based on Inhibition of Pathogen's Congress Banquet & Awards Ceremony 19:15 Cell-to-Cell Signaling and Consecutive Virulence Features Expression by Probiotic Signal Molecules Veronica Lazar, Ph.D.

University of Bucharest Bucharest, Romania

### Westin River North Hotel Chicago, IL USA June 28-July 1, 2014

TUESDAY, JULY 1 Registration / Breakfast / Exhibits 7:00 7:30 Satellite Symposium - Sponsor: BioK+ Primary Prevention of C. difficile Infection with Specific Probiotics Infections Stuart Johnson, M.D. Loyola University Stritch School of Medicine Hines VA Hospital Maywood, IL USA 8.30 Break Session XII: Vaginal Microbiome 8:45 Chair: Raina N. Fichorova, M.D, Ph.D. The Vaginal Microbiome: What's New Since Anaerobe 2012? 15:00 Break Jeanne Marrazzo, M.D. University of Washington 15:10 Seattle, WA USA Which Members of the Vaginal Microbiome are Associated with Amniotic Fluid Infections and PID? Sharon Hillier, M.D. Magee Women's Research Institute Pittsburgh, PA USA The Differential Roles of Vaginal Bacteria in Tuning Mucosal Immunitv Raina N. Fichorova, M.D, Ph.D. Brigham and Women's Hospital Boston. MA USA Effect of Intrauterine Contraception on Vaginal Microbiota Christine M. Bassis, Ph.D. 16:10 University of Michigan Ann Arbor, MI USA Chair: 10:00 Break 10:15 Session XIII: Clostridium difficile Epidemiology & Prevention Chair: Stuart Johnson, M.D. Update on the Epidemiology of C. difficile Infections from the CDC L. Clifford McDonald, M.D. Centers for Disease Control and Prevention Atlanta, GA USA New Insights into Clostridium difficile Transmission in the Hospital, Based on Whole Genome Sequencing Mark Wilcox, M.D. University of Leeds Leeds, UK difficile Developmental Progress of a Clostridium difficle Vaccine Patricia J. Freda Pietrobon, Ph.D. Sanofi Pasteur Swiftwater, PA USA Laboratory-Based Surveillance of Clostridium difficile Strains Thomas V Riley, Ph.D. The University of Western Australia Nedlands, Western Australia Does Binary Toxin Contribute to Clostridium difficile Infection? Germination Sarah Kuehne University of Nottingham Nottingham, United Kingdom 11:45 Lunch / Exhibits Poster Session 3 12:45 13.45Session XIV: Clostridium difficile Treatment & Immunity Chair: David M. Aronoff, M.D. Optimizing Existing Therapies for Clostridium difficile Infections Stuart Johnson, M.D. Loyola University Stritch School of Medicine Hines VA Hospital 17:40 Maywood, IL USA

Emerging Drugs and Vaccines Against Clostridium difficile Kevin Garey, Pharm.D. University of Houston College of Pharmacy Houston, TX USA A New Strategy for the Prevention of Clostridium difficile Ernesto Abel-Santos, Ph.D. University of Nevada, Las Vegas Las Vegas, NV USA Global Analysis of the Role of Inflammation in Clostridium difficile Colonization and Disease Gary B. Huffnagle, Ph.D. University of Michigan Ann Arbor, MI USA Session XV: Bacterial Therapy Chair: Vincent Young, M.D., Ph.D. Non-toxigenic Clostridium difficile to Prevent Recurrent Clostridium difficile Infections Dale Gerding, M.D. Hines VA Hospital Loyola University Chicago Stritch School of Medicine Maywood, IL USA Treatment Approaches for Resolving Recurrent Clostridium difficile Infection (RCID) Johan Bakken, M.D., Ph.D. St. Luke's Hospital Duluth, MN USA Session XVI: New Insights into Clostridium difficile Pathogenesis In-Depth Proteomic Analysis of the Toxigenic and Non-Toxigenic Clostridium difficile Secretome Hercules Moura. Ph.D. Centers for Disease Control and Prevention Atlanta GA USA Different Ways to Die: Epidemic-Associated Clostridium difficile Remodels Its Cell-Surface, and Manipulates the Host Innate Immune System to Cause Severe Disease Gavatri Vedantam. Ph.D. University of Arizona Tucson, AZ USA Intersection of Metabolism and Pathogenesis in Clostridium Laurent Bouillaut, Ph.D. Tufts University School of Medicine Boston, MA USA Conserved Oligopeptide Permeases Modulate Sporulation Initiation in Clostridium difficile Adrianne N. Edwards, Ph.D. Emory University Atlanta, GA USA Defining the Early Stages of Clostridium difficile Spore Joseph A. Sorg, Ph.D. Texas A&M University College Station, TX USA Complex Regulation of Clostridium difficile Biofilms Meera Unnikrishnan, Ph.D. The University of Warwick Medical School Coventry, United Kingdom Mechanisms of Iron Acquisition in Clostridium difficile Paul Carlson Jr., Ph.D. University of Michigan Ann Arbor, MI USA

Congress Ends